EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Bispecific Ligand‐Based EphB4 CAR‐T Cells Generated Using Ephrin‐B2 Show Potent Antitumor Activity Against Lung Adenocarcinoma

Hirotaka Kumeda, Koichi Hirabayashi iD, Shuji Mishima, Kotaro Morita, Yu Furui, Marina Fujioka, Tomoyuki Nakajima, Miyuki Tanaka, Yoshinori Sato, Takeshi Uehara iD, Shigeki Yagyu, Kimihiro Shimizu und 1 weitere

Cancer Science · 2026

DOI: 10.1111/cas.70397 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Hirotaka Kumeda und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Thoracic Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan. Hauptthemen laut MEDLINE: Receptor, EphB4, Adenocarcinoma of Lung, Ephrin-B2, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR)‐T cells generated using ephrin‐B2, the natural ligand for ephrin type‐B receptor 4 (EphB4), have demonstrated antitumor activity; however, their efficacy remains unvalidated. Therefore, we evaluated the dual‐targeting antitumor ability of these cells and confirmed their efficacy against lung adenocarcinoma. First, we evaluated EphB4 and EphA2 expression in samples from 74 patients with lung adenocarcinoma using immunohistochemistry. Next, EphB4 CAR‐T cells were generated via piggyBac ‐mediated gene transfer, and their phenotype was evaluated. Subsequently, we conducted an antigen stimulation assay to assess the bispecificity of the EphB4 CAR‐T cells. Finally, the antitumor effects of EphB4 CAR‐T cells on lung adenocarcinoma cell lines were assessed. EphB4 and EphA2 positivity in lung adenocarcinoma samples was 93% and 100%, respectively. EphB4 CAR‐T cells were successfully generated with high CAR positivity and a high proportion of naïve/stem cell memory‐like T cells. In the antigen stimulation assay, the cells responded in an antigen‐specific manner after stimulation with both EphB4 and EphA2 proteins. In the co‐culture experiment, EphB4 CAR‐T cells significantly suppressed the growth of all four lung adenocarcinoma cell lines compared to mock‐T cells. In vivo, mice treated with EphB4 CAR‐T cells displayed a significantly lower tumor burden than those treated with either CD19 CAR‐T cells or phosphate‐buffered saline. Additionally, mice treated with EphB4 CAR‐T cells survived significantly longer than those in the other groups. In conclusion, ligand‐based EphB4 CAR‐T cells are bispecific, targeting both EphB4 and EphA2. Furthermore, these cells exert significant antitumor effects against lung adenocarcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, EphB4Adenocarcinoma of LungEphrin-B2Lung NeoplasmsReceptors, Chimeric AntigenImmunotherapy, AdoptiveT-LymphocytesHumansAnimalsMiceReceptor, EphA2Cell Line, TumorFemaleMaleXenograft Model Antitumor AssaysMiddle AgedAgedLigands

Stichwörter der Autor:innen

piggyBacCAR‐T cellEphA2EphB4ephrin‐B2lung adenocarcinoma

Substanzen

Receptor, EphB4Ephrin-B2Receptor, EphA2EPHB4 protein, humanReceptors, Chimeric AntigenEPHA2 protein, humanLigands

Autor:innen und Institutionen

  • Division of General Thoracic Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
  • Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
  • Department of Obstetrics and Gynecology, Shinshu University School of Medicine, Matsumoto, Japan.
  • Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan.
  • Center for Advanced Research of Gene and Cell Therapy in Shinshu University (CARS), Shinshu University School of Medicine, Matsumoto, Japan.
  • A-SEEDS Co., Ltd., Matsumoto, Japan.

ORCID-Profile: Koichi Hirabayashi, Takeshi Uehara

Förderung

  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development

Zitieren

APA

Kumeda, H., Hirabayashi, K., Mishima, S., Morita, K., Furui, Y., Fujioka, M., Nakajima, T., Tanaka, M., Sato, Y., Uehara, T., Yagyu, S., Shimizu, K., & Nakazawa, Y. (2026). Bispecific Ligand‐Based EphB4 CAR‐T Cells Generated Using Ephrin‐B2 Show Potent Antitumor Activity Against Lung Adenocarcinoma. Cancer Science. https://doi.org/10.1111/cas.70397

Vancouver

Kumeda H, Hirabayashi K, Mishima S, Morita K, Furui Y, Fujioka M, et al. Bispecific Ligand‐Based EphB4 CAR‐T Cells Generated Using Ephrin‐B2 Show Potent Antitumor Activity Against Lung Adenocarcinoma. Cancer Science. 2026. doi:10.1111/cas.70397

BibTeX
@article{Kumeda2026,
  author = {Kumeda, Hirotaka and Hirabayashi, Koichi and Mishima, Shuji and Morita, Kotaro and Furui, Yu and Fujioka, Marina and Nakajima, Tomoyuki and Tanaka, Miyuki and Sato, Yoshinori and Uehara, Takeshi and Yagyu, Shigeki and Shimizu, Kimihiro and Nakazawa, Yozo},
  title = {Bispecific Ligand‐Based EphB4 CAR‐T Cells Generated Using Ephrin‐B2 Show Potent Antitumor Activity Against Lung Adenocarcinoma},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70397}
}
Kostenlos starten →